Copeptin (CTproAVP), a new tool for understanding the role of vasopressin in pathophysiology

Clinical Chemistry and Laboratory Medicine

Volumn 52, Issue 10, 2014, Pages 1447-1456

  Bolignano, Davide ^c   Cabassi, Aderville ^d   Fiaccadori, Enrico ^e   Ghigo, Ezio ^f   Pasquali, Renato ^g   Peracino, Andrea ^a,b   Peri, Alessandro ^h   Plebani, Mario ⁱ   Santoro, Antonio ^g   Settanni, Fabio ^j   Zoccali, Carmine ^c  

^a Fondazione Giovanni Lorenzini Medical Science Foundation   (Italy)

^b Urology and Renal Transplantation Unit ^*  (United States)

^c INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY OF PARMA MEDICAL SCHOOL   (Italy)

^f UNIVERSITY OF TURIN   (Italy)

^g UNIVERSITY OF BOLOGNA   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY HOSPITAL OF PADOVA   (Italy)

^j Diabetology and Metabolism   (Italy)

more..

Author keywords

Chronic heart failure; Copeptin; CTproAVP; Diabetes insipidus; Hyponatremia; Osmoregulation; Vasopressin

Indexed keywords

ARGIPRESSIN; COPEPTIN; GLYCOPEPTIDE;

ACUTE HEART FAILURE; CARBOXY TERMINAL SEQUENCE; DIABETES INSIPIDUS; HEART FAILURE; HORMONE RELEASE; HUMAN; HYPONATREMIA; INAPPROPRIATE VASOPRESSIN SECRETION; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; NEUROHYPOPHYSIS; OSMOREGULATION; PATHOPHYSIOLOGY; PLASMA OSMOLALITY; PRIORITY JOURNAL; REVIEW; STRESS; BLOOD; DISEASES;

ARGININE VASOPRESSIN; DISEASE; GLYCOPEPTIDES; HUMANS;

EID: 84919811775     PISSN: 14346621     EISSN: 14374331     Source Type: Journal    
DOI: 10.1515/cclm-2014-0379     Document Type: Review

References (54)

1. Laycock JF. Introduction to vasopressin. In: Perspectives on vasopressin. London: World Scientific Publishing Company, Imperial College Press, 2010;1-16.
2. Dedovic K, Duchesne A, Andrews J, Engert V, Pruessner JC. The brain and the stress axis: the neural correlates of cortisol regulation in response to stress. Neuroimage 2009;47:864-71.
3. Kvetnansky R, Sabban EL, Palkovits M. Catecholaminergic systems in stress: structural and molecular genetic approaches. Physiol Rev 2009;89:535-606.
4. Morgenthaler NG, Struck J, Jochberger S, Dünser MW. Copeptin: clinical use of a new biomarker. Trends Endocrinol Metab 2008;19:43-9.
5. Bolignano D, Zoccali C. Vasopressin beyond water: implications for renal diseases. Curr Opin Nephrol Hypertens 2010;19:499-504.
6. Holmes CL, Landry DW, Granton JT. Science review: vasopressin and the cardiovascular system part 1 - receptor physiology. Crit Care 2003;7:427-34.
7. Holt NF, Haspel KL. Vasopressin: a review of therapeutic applications. J Cardiothorac Vasc Anesth 2010;24:330-47.
8. Zerbe RL, Vinicor F, Robertson GL. Plasma vasopressin in uncontrolled diabetes mellitus. Diabetes 1979;28:503-8.
9. Spruce BA, McCulloch AJ, Burd J, Orskov H, Heaton A, Baylis PH, et al. The effect of vasopressin infusion on glucose metabolism in man. Clin Endocrinol (Oxf) 1985;22:463-8.
10. Enhörning S, Wang TJ, Nilsson PM, Almgren P, Hedblad B, Berglund G, et al. Plasma copeptin and the risk of diabetes mellitus. Circulation 2010;121:2102-8.
11. Hiroyama M, Aoyagi T, Fujiwara Y, Birumachi J, Shigematsu Y, Kiwaki K, et al. Hypermetabolism of fat in V1a vasopressin receptor knockout mice. Mol Endocrinol 2007;21:247-58.
12. Küchler S, Perwitz N, Schick RR, Klein J, Westphal S. Argininevasopressin directly promotes a thermogenic and pro-inflammatory adipokine expression profile in brown adipocytes. Regul Pept 2010;164:126-32.
13. Bhandari SS, Loke I, Davies JE, Squire IB, Struck J, Ng LL. Gender and renal function influence plasma levels of copeptin in healthy individuals. Clin Sci (Lond) 2009;116:257-63.
14. Morgenthaler NG, Struck J, Alonso C, Bergmann A. Assay for the measurement of copeptin, a stable peptide derived from the precursor of vasopressin. Clin Chem 2006;52:112-9.
15. Balanescu S, Kopp P, Gaskill MB, Morgenthaler NG, Schindler C, Rutishauser J. Correlation of plasma copeptin and vasopressin concentrations in hypo-, iso-, and hyperosmolar states. J Clin Endocrinol Metab 2011;96:1046-52.
16. Fenske W, Störk S, Blechschmidt A, Maier SG, Morgenthaler NG, Allolio B. Copeptin in the differential diagnosis of hyponatremia. J Clin Endocrinol Metab 2009;94:123-9.
17. Blanchard A, Steichen O, De Mota N, Curis E, Gauci C, Frank M, et al. An abnormal apelin/vasopressin balance may contribute to water retention in patients with the syndrome of inappropriate antidiuretic hormone (SIADH) and heart failure. J Clin Endocrinol Metab 2013;98:2084-9.
18. Robertson GL. Diabetes insipidus. Endocrinol Metab Clin North Am 1995;24:549-72.
19. Moeller HB, Rittig S, Fenton RA. Nephrogenic diabetes insipidus: essential insights into the molecular background and potential therapies for treatment. Endocr Rev 2013;34:278-301.
20. Fenske W, Allolio B. Clinical review: current state and future perspectives in the diagnosis of diabetes insipidus: a clinical review. J Clin Endocrinol Metab 2012;97:3426-37.
21. Nemergut EC, Zuo Z, Jane JA, Laws ER Jr. Predictors of diabetes insipidus after transsphenoidal surgery: a review of 881 patients. J Neurosurg 2005;103:448-54.
22. Aleksandrov N, Audibert F, Bedard MJ, Mahone M, Goffinet F, Kadoch IJ. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010;32:225-31.
23. Kalelioglu I, Kubat Uzum A, Yildirim A, Ozkan T, Gungor F, Has R. Transient gestational diabetes insipidus diagnosed in successive pregnancies: review of pathophysiology, diagnosis, treatment, and management of delivery. Pituitary 2007;10:87-93.
24. Szinnai G, Morgenthaler NG, Berneis K, Struck J, Müller B, Keller U, et al. Changes in plasma copeptin, the c-terminal portion of arginine vasopressin during water deprivation and excess in healthy subjects. J Clin Endocrinol Metab 2007;92:3973-8.
25. Katan M, Morgenthaler NG, Dixit KC, Rutishauser J, Brabant GE, Müller B, et al. Anterior and posterior pituitary function testing with simultaneous insulin tolerance test and a novel copeptin assay. J Clin Endocrinol Metab 2007;92:2640-3.
26. Fenske W, Quinkler M, Lorenz D, Zopf K, Haagen U, Papassotiriou J, et al. Copeptin in the differential diagnosis of the polydipsia- polyuria syndrome - revisiting the direct and indirect water deprivation tests. J Clin Endocrinol Metab 2011;96:1506-15.
27. Verbalis JG, Goldsmith SR, Greenberg A, Korzelius C, Schrier RW, Sterns RH, et al. Diagnosis, evaluation, and treatment of hyponatremia: expert panel recommendations. Am J Med 2013;126:S1-42.
28. Miller M, Morley JE, Rubenstein LZ. Hyponatremia in a nursing home population. J Am Geriatr Soc 1995;43:1410-3.
29. Kinsella S, Moran S, Sullivan MO, Molloy MG, Eustace JA. Hyponatremia independent of osteoporosis is associated with fracture occurrence. Clin J Am Soc Nephrol 2010;5:275-80.
30. Corona G, Giuliani C, Parenti G, Norello D, Verbalis JG, Forti G, et al. Moderate hyponatremia is associated with increased risk of mortality: evidence from a meta-analysis. PLoS One 2013;8:e80451.
31. Esposito P, Piotti G, Bianzina S, Malul Y, Dal Canton A. The syndrome of inappropriate antidiuresis: pathophysiology, clinical management and new therapeutic options. Nephron Clin Pract 2011;119:c62-73.
32. Feldman BJ, Rosenthal SM, Vargas GA, Fenwick RG, Huang EA, Matsuda-Abedini M, et al. Nephrogenic syndrome of inappropriate antidiuresis. N Engl J Med 2005;352:1884-90.
33. Stoiser B, Mörtl D, Hülsmann M, Berger R, Struck J, Morgenthaler NG, et al. Copeptin, a fragment of the vasopressin precursor, as a novel predictor of outcome in heart failure. Eur J Clin Invest 2006;36:771-8.
34. Morgenthaler NG. Copeptin: a biomarker of cardiovascular and renal function. Congest Heart Fail 2010;16(Suppl 1):S37-44.
35. Yalta K, Yalta T, Sivri N, Yetkin E. Copeptin and cardiovascular disease: a review of a novel neurohormone. Int J Cardiol 2013;167:1750-9.
36. Finley JJ, Konstam MA, Udelson JE. Arginine vasopressin antagonists for the treatment of heart failure and hyponatremia. Circulation 2008;118:410-21.
37. Maisel A, Xue Y, Shah K, Mueller C, Nowak R, Peacock WF, et al. Increased 90-day mortality in patients with acute heart failure with elevated copeptin: secondary results from the biomarkers in acute heart failure (BACH) study. Circ Heart Fail 2011;4:613-20.
38. Balling L, Kistorp C, Schou M, Egstrup M, Gustafsson I, Goetze JP, et al. Plasma copeptin levels and prediction of outcome in heart failure outpatients: relation to hyponatremia and loop diuretic doses. J Card Fail 2012;18:351-8.
39. Peacock WF, Nowak R, Christenson R, Di Somma S, Neath SX, Hartmann O, et al. Short-term mortality risk in emergency department acute heart failure. Acad Emerg Med 2011;18:947-58.
40. Di Somma S, Magrini L, Travaglino F, Lalle I, Fiotti N, Cervellin GF, et al. Opinion paper on innovative approach of biomarkers for infectious diseases and sepsis management in the emergency department. Clin Chem Lab Med 2013;51:1167-75.
41. Meijer E, Bakker SJ, van der Jagt EJ, Navis G, de Jong PE, Struck J, et al. Copeptin, a surrogate marker of vasopressin, is associated with disease severity in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2011;6:361-8.
42. Dünser MW, Schmittinger CA, Torgersen C. Copeptin and the transplanted kidney: friends or foes? Transplantation 2009;88:455-6.
43. Boertien WE, Meijer E, Li J, Bost JE, Struck J, Flessner MF, et al. Relationship of copeptin, a surrogate marker for arginine vasopressin, with change in total kidney volume and GFR decline in autosomal dominant polycystic kidney disease: results from the CRISP cohort. Am J Kidney Dis 2013;61:420-9.
44. Bankir L, Bouby N, Ritz E. Vasopressin: a novel target for the prevention and retardation of kidney disease? Nat Rev Nephrol 2013;9:223-39.
45. Boertien WE, Meijer E, Zittema D, van Dijk MA, Rabelink TJ, Breuning MH, et al. Copeptin, a surrogate marker for vasopressin, is associated with kidney function decline in subjects with autosomal dominant polycystic kidney disease. Nephrol Dial Transplant 2012;27:4131-7.
46. Zittema D, Boertien WE, van Beek AP, Dullaart RP, Franssen CF, de Jong PE, et al. Vasopressin, copeptin, and renal concentrating capacity in patients with autosomal dominant polycystic kidney disease without renal impairment. Clin J Am Soc Nephrol 2012;7:906-13.
47. Ho TA, Godefroid N, Gruzon D, Haymann JP, Maréchal C, Wang X, et al. Autosomal dominant polycystic kidney disease is associated with central and nephrogenic defects in osmoregulation. Kidney Int 2012;82:1121-9.
48. Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med 2012;367:2407-18.
49. Torres VE, Bankir L, Grantham JJ. A case for water in the treatment of polycystic kidney disease. Clin J Am Soc Nephrol 2009;4:1140-50.
50. Barash I, Ponda MP, Goldfarb DS, Skolnik EY. A pilot clinical study to evaluate changes in urine osmolality and urine cAMP in response to acute and chronic water loading in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol 2010;5:693-7.
51. Wang CJ, Creed C, Winklhofer FT, Grantham JJ. Water prescription in autosomal dominant polycystic kidney disease: a pilot study. Clin J Am Soc Nephrol 2011;6:192-7.
52. Lippi G, Plebani M, Di Somma S, Monzani V, Tubaro M, Volpe M, et al. Considerations for early acute myocardial infarction ruleout for emergency department chest pain patients: the case of copeptin. Clin Chem Lab Med 2012;50:243-53.
53. Manolio T. Novel risk markers and clinical practice. N Engl J Med 2003;349:1587-9.
54. Spasovski G, Vanholder R, Allolio B, Annane D, Ball S, Bichet D, et al, on behalf of the Hyponatraemia Guideline Development Group. Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol 2014;170:G1-47.